AstraZeneca's (AZN) leading presence in the pharma and biotech industry is built on patent-protected drugs and a developing pipeline that all add up to a wide moat. The firm's dynamic operations and an aggressive acquisition strategy create growth opportunities to offset patent losses, including the near-term expirations of neurology drug Seroquel and oncology drug Arimidex.
Although AstraZeneca's pipeline ranks toward the bottom of its peer group, we think the company is developing several key products that hold blockbuster potential. In particular, dapagliflozin could enjoy a first-mover advantage as a new type of diabetes therapy.
Although the company creates growth opportunities through acquisitions, its checkered track record leaves us less confident of management's adherence to price discipline.
Additionally, besides both internal and external product development, Astra is significantly cutting costs to mitigate lost profits from products losing patent protection. The cost savings should help the company navigate the patent losses on several high-margin drugs.
Morningstar Analyst Notes and Research are available to Premium subscribers. Sign up for a free two-week trial for instant access to the full research report on AstraZeneca, including our fair value estimate and economic moat.